Timo Joensuu1, Greetta Joensuu2,3, Kalevi Kairemo2,4, Timo Kiljunen2, Maigo Riener2, Aili Aaltonen2, Martti Ala-Opas2, Aki Kangasmäki2, Tuomo Alanko2, Lauri Taipale2,5, Petteri Hervonen2,6, Anna Bützow7, Irene Virgolini8, Akseli Hemminki2,5,9. 1. Docrates Cancer Center, Helsinki, Finland timo.joensuu@docrates.com. 2. Docrates Cancer Center, Helsinki, Finland. 3. Doctoral Programme of Clinical Research, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland. 4. Department of Nuclear Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A. 5. Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland. 6. Department of Oncology, Tampere University Hospital, Tampere, Finland. 7. United MEDIX Laboratories Ltd., Espoo, Finland. 8. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria. 9. Cancer Gene Therapy Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Abstract
AIM: We combined anti-androgen therapy with radiotherapy in a first-line setting for metastatic prostate cancer aiming to cause maximal cancer-cell death to delay the emergence of castration-resistant disease. MATERIALS AND METHODS: In this non-randomized retrospective series of 46 patients, the initial median prostate-specific antigen (PSA) was 98.5 μg/l (range=6.7-15,500), median Gleason score 9 and most men had at least T3N1M1 disease. All patients received luteinizing hormone releasing hormone analog or degarelix with bicalutamide. If PSA remained above 1 μg/l, docetaxel was initiated. At PSA nadir, all patients received radical radiotherapy of the prostate. RESULTS: The median follow-up time was 4.38 years (range=0.36-11.24). Most radiotherapy-related adverse events were grade 1 and transient. There were no grade 4 events. Overall survival (OS) at 5 years was 81.3%. CONCLUSION: The feasibility and safety of aggressive multimodality treatment were good resulting in an excellent median OS of 8.35 years. Copyright
AIM: We combined anti-androgen therapy with radiotherapy in a first-line setting for metastatic prostate cancer aiming to cause maximal cancer-cell death to delay the emergence of castration-resistant disease. MATERIALS AND METHODS: In this non-randomized retrospective series of 46 patients, the initial median prostate-specific antigen (PSA) was 98.5 μg/l (range=6.7-15,500), median Gleason score 9 and most men had at least T3N1M1 disease. All patients received luteinizing hormone releasing hormone analog or degarelix with bicalutamide. If PSA remained above 1 μg/l, docetaxel was initiated. At PSA nadir, all patients received radical radiotherapy of the prostate. RESULTS: The median follow-up time was 4.38 years (range=0.36-11.24). Most radiotherapy-related adverse events were grade 1 and transient. There were no grade 4 events. Overall survival (OS) at 5 years was 81.3%. CONCLUSION: The feasibility and safety of aggressive multimodality treatment were good resulting in an excellent median OS of 8.35 years. Copyright